Long-term Outcomes of Coronary Artery Bypass Grafting in Veterans with Left Main Coronary Artery Disease

Sheena W. Chen, MD,1,2 Ethan Rosenfeld, MD,1,2 K. Benjamin Lee, MD,1,2 Michael Napolitano, MD,1,2 Andrew D. Sparks, MS,2 Jeffrey Panting-Crespo, MD,1 Gregory D. Trachiotis, MD1

1Division of Cardiothoracic Surgery and Heart Center, Washington D.C. Veterans Affairs Medical Center, Washington, D.C., USA; 2Department of Surgery, George Washington University, Washington, D.C., USA

ABSTRACT

Background: Studies of the civilian population with left main coronary artery disease (LMCAD) who underwent coronary artery bypass grafting (CABG) have shown 2% to 4.2% 30-day mortality. However, there is a lack of reporting from the veteran population. Here we analyze the outcomes of veterans with LMCAD who underwent CABG by a single surgeon at a single Veterans Affairs Medical Center (VAMC).

Methods: Veterans who underwent isolated CABG between 1998 to 2018 at a VAMC were further divided into a group with significant left main coronary artery disease (LMCAD) of stenosis greater than or equal to 50% and a group without left main coronary artery stenosis (non-LMCAD). The primary outcome was mortality. Secondary outcomes included postoperative complications. Multivariable regression analysis and Kaplan-Meier survival analysis were used to compare the two cohorts.

Results: The demographics and comorbidities are similar between the two cohorts except for higher average age and percentage of stroke in the LMCAD group (n = 509) compared to non-LMCAD (n = 927). Perioperative complications are comparable between the two groups except for increased length of stay (LOS) in the LMCAD group (12.9 ± 15.9 days versus 10.9 ± 9.0 days in non-LMCAD, P < .001). 30-day mortality in the LMCAD group is 4.1% versus 1.4% in non-LMCAD. However, Kaplan-Meier curves show no significant difference in adjusted overall survival throughout 15 years between the groups (P = .560).

Conclusion: Veterans with LMCAD who underwent CABG have similar postoperative complications compared to non-LMCAD group. The 30-day mortality is higher in the LMCAD group; however, there is no difference in long-term survival.

INTRODUCTION

Left main coronary artery disease (LMCAD) is the highest risk subset of coronary artery disease given the wide area of myocardium threatened by ischemia [Cho 2019; Harskamp 2015; Lee 2016]. Accordingly, revascularization remains the standard of care for those with significant disease (>50% stenosis) regardless of the presence or absence of symptoms [Authors/Task Force members 2014; Fihn 2014; Ramadan 2018]. Historically, coronary artery bypass grafting (CABG) has been the standard of care for revascularization while percutaneous coronary interventions (PCI) is reserved for patients with high surgical risk [Harskamp 2015]. However, with advancements in percutaneous methods and efficacy over the past two decades, PCI has emerged as a viable alternative to open surgical revascularization in more instances, particularly for less complex lesions [Ramadan 2018].

At present, multiple clinical trials and pooled analysis of individual data from previous trials have not shown a clear survival benefit for either CABG or PCI with regard to LMCAD specifically [Buszman 2016; Head 2018]. Trends in the literature show improved long-term durability of revascularization and associated improved long-term morbidity outcomes with CABG as compared to PCI; however, these benefits come at the drawback of a slightly higher risk of immediate perioperative morbidity [Morice 2010; Morice 2014; Nerlekar 2016; Stone 2016]. Nevertheless, improvements in surgical techniques and technologies as well as periprocedural care have made undergoing CABG progressively safer than in the past [Alexander 2016; Modolo 2019].

Appreciating the perioperative risk profile associated with CABG in contemporary surgical practice is important in guiding therapeutic decisions, particularly with strong alternative options available. Determining which strategy to undertake for revascularization of LMCAD is a complex decision-making process that requires patient personalization. Specifics of the patient’s health status, their cardiovascular pathology, and additional knowledge of institution specific factors should all be taken into account. As a result of individualization of care in patients with cardiac diseases, trials in the civilian population have shown that over the past decade morbidity and mortality outcomes for CABG for LMCAD have improved. For instance, a decreased rate in major adverse cardiovascular or cerebrovascular events (MACCE) was noted in the Evaluation of Xience Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial (2010-2014) as compared to the older Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) trial (2005-2007) [Modolo 2019]. However, while outcomes of CABG...
procedures for LMCAD in non-governmental hospitals are well reported, little is known about the recent outcomes in veteran populations at Department of Veterans Affairs (VA) medical centers. This distinction is important because veterans experience a higher than usual burden of cardiovascular disease, and are generally presumed to be higher risk patients [Scherer 2019]. Therefore, it is unclear if results of civilian populations can be generalized to this population and used when guiding patient selection and preoperative risk counseling. The purpose of this study was to benchmark outcomes of veterans with LMCAD who underwent CABG by a single surgeon at a single VA over the past 20 years.

**MATERIALS AND METHODS**

This is a retrospective study of a prospectively collected database from a single cardiothoracic surgeon at a Veterans Affairs Medical Center (VAMC). All patients who underwent isolated CABG for all indications and level of operative priority between 1998 to 2018 were divided into a group with significant left main coronary artery disease (LMCAD) of stenosis greater or equal to 50% and a group without any left main coronary artery stenosis (non-LMCAD). The patients who had mild left main coronary artery stenosis were excluded from the study. There was no age restriction.

Clinically relevant preoperative, intraoperative, and operative variables with $P < .2$ in univariate between group comparisons were considered possible confounding variables and were adjusted for in multivariate logistic regression modeling using backwards selection of variables. Cumulative mortality events were calculated using Kaplan-Meier survival analysis with time-to-event and censoring calculated from the date of the surgery to the date of last encounter or death. The primary outcome of interest was mortality at 30 days, 5-year, and 10-year. Secondary outcomes were cardiovascular, pulmonary, and renal composite morbidity outcomes, as well as unplanned reoperation and wound complications.

### Table 1. Comparison of Preoperative Variables between Non-LMCAD and LMCAD Cohort

| Pre-Op Variable | Non-LMCAD (n = 927) | LMCAD (n = 509) | P  |
|-----------------|---------------------|----------------|----|
| Age             | 63.6 ± 9.1          | 66.7 ± 9.4     | <.001 |
| Sex, male       | 915 (98.7)          | 505 (99.2)     | .38 |
| COPD            | 384 (41.4)          | 210 (41.3)     | .95 |
| Current smoker  | 277 (29.9)          | 160 (31.4)     | .54 |
| Cerebral vascular disease | 159 (17.2) | 122 (24.0) | .002 |
| Diabetes        | 385 (41.5)          | 207 (40.7)     | .75 |
| Prior PTCA      |                     |                |    |
| 0               | 847 (91.4)          | 76 (8.2)       |    |
| 1               | 0 (0.4)             | 495 (97.3)     |    |
| 2               | 13 (2.6)            | 1 (0.2)        |    |
| Prior cardiac surgery | 14 (1.5) | 12 (2.4) | .25 |
| Preoperative IABP | 85 (9.2)         | 86 (16.9)      | <.001 |
| Prior MI        |                     |                |    |
| 0               | 443 (47.8)          | 388 (41.9)     |    |
| 1               | 96 (10.4)           | 256 (50.3)     | .028 |
| 2 or more       | 182 (35.8)          | 71 (14.0)      |    |
| PVD             | 254 (27.4)          | 164 (32.2)     | .054* |
| HTN             | 736 (79.4)          | 427 (83.9)     | .55 |
| BMI             | 29.4 ± 5.8          | 28.7 ± 5.3     |    |
| 28.7 (25.5, 32.5)| 28.2 ± 5.3          | 27.9 (24.7, 30.9)| <.001 |
| Albumin         | 3.83 ± 0.47         | 3.80 ± 0.47    | .18* |
| Creatinine      | 1.31 ± 1.01         |                |    |
| Hemoglobin      | 13.40 ± 1.66        | 13.13 ± 1.65   | .004 |
| HDL             | 37.93 ± 9.04        |                |    |
| 38 (34, 39)     | 39.53 ± 9.59        |                |    |
| 38 (35, 42)     | .002                |                |    |
| LDL             | 103.51 ± 29.55      |                |    |
| 100 (96, 108)   | 104.18 ± 30.12      |                |    |
| 100 (93, 110.2)| .82                 |                |    |
| ASA Score       | 292 (31.5)          | 635 (68.5)     | .014 |
| 2 or 3          | 129 (25.3)          | 380 (74.7)     |    |
| 4 or 5          |                     |                |    |
| LAD % stenosis  | 80.9 ± 17.7         | 64.4 ± 31.5    | <.001 |
| 85 (70, 90)     | 75 (50, 90)         |                |    |
| RCA % stenosis  | 67.5 ± 34.9         | 68.9 ± 34.0    | .45 |
| 80 (50, 99)     | 80 (50, 90)         |                |    |
| CIRC % stenosis | 58.3 ± 36.5         | 59.5 ± 36.3    | .56 |
| 70 (30, 90)     | 70 (30, 90)         |                |    |

Values are reported as n (%), mean ± SD if relatively normally distributed, mean ± SD and median (IQR) if nonparametric; Bold $P$ values <.05 are statistically significant; *$P < .2$ is trend-level significant. LMCAD indicates left main coronary artery disease; COPD, chronic obstructive pulmonary disease; PTCA, percutaneous transluminal coronary angioplasty; IABP, intra-aortic balloon pump; MI, myocardial infarction; PVD, peripheral vascular disease; HTN, hypertension; LDL, low density lipoprotein; ASA, American Society of Anesthesiologists; LAD, left anterior descending coronary artery; RCA, right coronary artery; CIRC, circumflex artery; LM, left main coronary artery.

---

$\text{E532}$
subgroup analysis was performed in patients with LMCAD who were sub-stratified based on whether cardiopulmonary bypass was used (off-pump CABG (OPCAB) versus on-pump CABG (ONCAB)). Chi-square or Fisher exact test were used for categorical variables and independent t test or Kruskal-Wallis test for continuous variables. All statistical analysis was performed using JMP Pro14 (SAS Institute, Cary, NC, USA).

Of note, the CABGs are performed off-pump unless patients have active angina, LMCAD with reduced left ventricular function, diffuse CAD, non-healthy target vessel, or if the bypass needs extensive lateral wall manipulation. For perfusion, we used 4:1 blood delivered antegrade throughout the case. Our solution uses a Plegisol (Pfizer) base with 100 mg Lidocaine, 10 g mannitol, 11 mEq sodium bicarbonate, and 40 mEq potassium chloride. The cardioplegia is delivered at a temperature of 4 degrees Celsius. ONCABGs are typically only vented through the aortic root.

### RESULTS

Between January 1998 and December 2017, 509 patients who underwent CABG had LMCAD greater than or equal to 50% stenosis (LMCAD group) while 927 patients did not have any left main coronary artery (non-LMCAD group) at the DC VAMC. The patients were on average 64.7 years old and a majority were male (98.9%), with an average BMI of 28.97. The demographics were similar between the two cohorts except for average older age in the LMCAD group (66.7 ± 9.4 versus 63.6 ± 9.1 years old, \( P < .001 \)). The LMCAD group also had significantly higher percentage of cerebrovascular diseases (24.0% versus 17.2%), prior percutaneous transluminal coronary angioplasty (PTCA) (97.3% versus 91.4%, \( P < .001 \)), prior MI within 7 days of CABG (14.0% versus 10.4%, \( P = .028 \)), higher American Society of Anesthesiologists (ASA) score (74.7% versus 68.5% ASA score 4 or 5, \( P = .014 \)), and higher preoperative intraaortic balloon pump (IABP) (16.9% versus 9.2%, \( P < .001 \)) (Table 1). The non-LMCAD group had significantly more patients with prior MI more than 7 days before the CABG (41.9% versus 35.8%, \( P = .028 \)), prior BMI (29.4 ± 5.8 versus 28.2 ± 5.3, \( P < .001 \)), lower high-density lipoproteins (HDL) (37.93 ± 9.04 versus 39.53 ± 9.59, \( P = .002 \)), and higher left anterior descending (LAD) artery percent stenosis (80.9% ± 17.7 versus 64.4% ± 31.5, \( P < .001 \)) than the LMCAD group (Tables 1 and 2).

| Operative Variable | Non-LMCAD (n = 927) | LMCAD (n = 509) | \( P \) |
|--------------------|---------------------|----------------|------|
| Priority           |                     |                |      |
| Elective           | 860 (92.8)          | 460 (90.4)     |      |
| Urgent             | 57 (6.2)            | 40 (7.9)       | .27  |
| Emergent           | 10 (1.1)            | 9 (1.8)        |      |
| Operative time, min| 227.9 ± 70.9        | 228.5 ± 73.8   | .57  |
| ONCABG             | 376 (40.6)          | 230 (45.2)     | .21  |
| Bypass time, min   | (OPCABG n = 376)    | (ONCABG n = 230)|      |
|                    | 92.2 ± 35.2         | 89.4 ± 31.0    | .18  |
|                    | 89 (3, 264)         | 84.5 (6, 240)  |      |
| Cross clamp time, min| (OPCABG n = 376) | (ONCABG n = 230)|      |
|                    | 51.9 ± 27.5         | 49.1 ± 24.7    | .26  |
|                    | 50 (0, 157)         | 50 (0, 120)    |      |

Values are reported as mean ± SD if relatively normally distributed, mean ± SD and median (IQR) if nonparametric. LMCAD indicates left main coronary artery disease; OPCAB, off-pump CABG; ONCAB, on-pump CABG.
DISCUSSION

Some of the first randomized trials that showed CABG to be superior to medical treatment for patients with greater than 75% left main stenosis and left ventricular dysfunction were studies done in the VA system in the 1980s and 1990s [Takaro 1982; Vaughan-Sarrazin 2007]. However, subsequent literature on LMCAD outcomes since the 90s has almost exclusively come from the civilian population. The outcomes of LMCAD patients who underwent CABG after 1995 showed that the 30-day mortality ranged between 3% and 4.2% and the survival at two years was approximately 95% [VA Coronary Artery Bypass Surgery Cooperative Study Group 1992].

30-day mortality of LMCAD patients who underwent CABG continued to decrease in the civilian population. Given that previous studies have shown the veteran population to be a much higher risk cohort with a more severe comorbidity profile as compared to civilians, it is unclear whether the surgical care of veterans undergoing CABG for LMCAD has made the same strides as have been shown in the civilian setting [Morce 2014; Nerlekar 2016; Taggart 2008]. In this study, we evaluated 30-day morbidity and mortality outcomes as well as long-term mortality outcomes of veterans undergoing CABG for LMCAD. Through a retrospective review of prospectively collected records of veterans undergoing CABG for LMCAD at a single VA medical center over a 20-year period, we found that veterans with LMCAD who underwent CABG have similar postoperative complications and long-term mortality compared to non-LMCAD patients.

The 30-day mortality was significantly higher in the LMCAD group compared to the non-LMCAD group in this study (4.1% versus 1.4%, \( P = .016 \), Table 3) however, the long-term mortality in both the unadjusted survival and multivariable Cox-proportional regression model Kaplan-Meier survival

| Post-Op Variable                  | Non-LMCAD (n = 927) | LMCAD (n = 509) | \( P \) | aOR (95% CI) | Adjusted \( P \) |
|-----------------------------------|---------------------|----------------|--------|--------------|----------------|
| Perioperative MI                   | 13 (1.4)            | 3 (0.6)        | .16    | 0.33 (0.11–0.96) | .042           |
| Renal failure                     | 5 (0.5)             | 6 (1.2)        | .21    | 1.16 (0.42–3.27) | .77            |
| Mediastinitis                     | 8 (0.9)             | 3 (0.6)        | .76    | 0.62 (0.22–1.79) | .38            |
| Cardiac arrest, CPR               | 17 (1.8)            | 10 (2.0)       | .86    | 0.90 (0.42–1.92) | .78            |
| Reop for bleeding                 | 20 (2.2)            | 6 (1.2)        | .21    | 0.63 (0.27–1.47) | .28            |
| Ventilator > 48 hours             | 51 (5.5)            | 34 (6.7)       | .37    | 0.69 (0.40–1.21) | .20            |
| Stroke                            | 3 (0.3)             | 1 (0.2)        | .83    | 2.31 (0.58–9.21) | .24            |
| 30-day mortality                  | 13 (1.4)            | 21 (4.1)       | .001   | 2.32 (1.17–4.62) | .016           |
| 180-day mortality                 | 31 (3.3)            | 26 (5.1)       | .10    | 1.40 (0.77–2.55) | .27            |
| Total mortality                   | 254 (27.4)          | 154 (30.3)     | .25    | 0.92 (0.69–1.23) | .57            |
| MACCE                             | 36 (3.9)            | 27 (5.3)       | .21    | 1.09 (0.61–1.95) | .78            |

| Composite                         |                     |                |        |              |            |
|-----------------------------------|---------------------|----------------|--------|--------------|----------------|
| 0                                 | 839 (90.5)          | 454 (89.2)     |        |              |                |
| 1                                 | 59 (6.4)            | 36 (7.1)       |        |              |                |
| 2                                 | 20 (2.2)            | 12 (2.4)       |        |              |                |
| 3                                 | 4 (0.4)             | 5 (1.0)        | .19    | –            | –              |
| 4                                 | 5 (0.5)             | –              |        |              |                |
| 5                                 | –                   | 1 (0.2)        |        |              |                |
| 6                                 | –                   | 1 (0.2)        |        |              |                |
| Binary composite                  | 88 (9.5)            | 55 (10.8)      | .43    | 0.82 (0.53–1.25) | .35           |
| Postoperative LOS                 | 10.9 ± 9.0          | 12.9 ± 15.9    | <.001  | aOR N/A      |                |
| ICU LOS                           | 2.8 ± 3.3           | 3.2 ± 5.2      | .006   | aOR N/A      |                |

Values are reported as n (%), mean ± SD if normally distributed, mean ± SD and median (IQR) if non-parametric; bold \( P \) values <.05 are statistically significant. LMCAD indicates left main coronary artery disease; MI, myocardial infarction; MACCE, major adverse cardiovascular or cerebrovascular events; LOS, length of stay.
curve showed no difference in survival in 10 years (Figures 1 and 2). LMCAD patients have had better results over the years as the perioperative care for CABG improved with preoperative IABP use, increased use of transesophageal ultrasonography, better imaging quality, and optimized postoperative ICU care (Table 4) [Deppe 2017; Lee 2016; Taggart 2008].

Compared to the randomized EXCEL and SYNTAX trials, which had 75-77% male patients, veterans in our study were similar in age and BMI but had significantly higher percentage of male (98.9%) than the LMCAD patients who underwent CABG [Lee 2016; Morice 2014]. Notably, veterans had significantly higher comorbidities than the civilian population reported in the EXCEL and SYNTAX trials; LMCAD patients in our study were 49.7% with prior MI (versus 16.9% and 25.4%, respectively in EXCEL and SYNTAX), 31.4% current smoker (versus 20.8% and 24.0%), 40.7% diabetic (versus 28.0% and 25.6%), 83.9% hypertensive (versus 62.4% and 66.9%), 41.3% with COPD (versus 8.5%), and 32.2% with PVD (versus 8.8%) (Table 1) [Lee 2016; Morice 2014]. Despite having significantly higher comorbidities, the veterans in our study had fewer 30-day postoperative complications such as perioperative MI (0.6%) and stroke (0.2%) when compared to patients in the EXCEL trial (n = 957, 6.2% and 1.3%, respectively) [Lee 2016]. Our patients also had similar postoperative LOS to that in SYNTAX (12.9 ± 15.9 versus 13.6 ± 9.6 days) [Morice 2014].

In the subanalysis between ONCAB and OPCAB in our LMCAD cohort, 30-day postoperative outcomes were similar except that OPCAB had statistically significantly shorter LOS (12.7 ± 18.7 days versus 13.2 ± 11.7 days, adjusted P < .01) (Table 5). The 30-day, 180-day, and all-time mortality were no different between ONCAB and OPCAB groups, contrary to the finding in ROOBY trial (Table 5) [Deppe 2017]. The ROOBY trial reported that OPCAB in general had higher mortality and more adverse events than ONCAB patients at five-year follow up [Deppe 2017]. The use of OPCAB has decreased in the United States in the past decade likely due to multiple studies that associated OPCAB with less complete revascularization that resulted in worse long-term graft patency than ONCAB [Deppe 2017; Shroyer 2017]. The ROOBY trial was carried out in the VA system with average surgeon experience of 120 cases of OPCAB prior to the trial [Deppe 2017]. However, the primary surgeons were a mix of attending surgeons and residents in multiple different VAMCs [Deppe 2017]. Our study was free of surgeon and cardiac team variability, and our subanalysis results would support performing OPCAB in LMCAD patients in the care of an experienced surgeon and cardiac team that is proficient in OPCAB.

The success of our cardiothoracic surgery team lies in the consistency of the surgery team and optimization of the perioperative management in collaboration with the cardiology

| Table 4. Overall Survival with Time |
|-----------------------------------|
| **Time** | **Non-LMCAD (n = 927)** | **LMCAD (n = 509)** |
| 1 year | 94.8% (93.4%–96.3%) | 91.0% (88.4%–93.5%) |
| 2 year | 91.1% (89.2%–92.9%) | 85.7% (82.6%–88.8%) |
| 5 year | 81.3% (78.8%–83.9%) | 75.1% (71.2%–78.9%) |
| 10 year | 73.9% (71.0%–76.8%) | 69.9% (65.9%–74.0%) |

LMCAD indicates left main coronary artery disease.

| Table 5. Outcomes by Off- versus On-Pump in LMCAD Cohort, with Multivariable Logistic Regression |
|------------------------------------------|
| **Post-Op Variable** | **Off-Pump (n = 279)** | **On-Pump (n = 230)** | **P** | **aOR On versus Off (95% CI)** | **Adjusted P** |
| 30-day mortality | 7 (2.5) | 4 (1.7) | .76 | 0.77 (0.21 – 2.78) | .69 |
| 180-day mortality | 18 (6.5) | 8 (3.5) | .13 | 0.65 (0.27 – 1.56) | .34 |
| Total mortality | 84 (30.1) | 70 (30.4) | .94 | 1.60 (0.96 – 2.67) | .07 |
| Postoperative LOS | 12.7 ± 18.7 | 13.2 ± 11.7 | .012 | | |
| ICU LOS | 3.2 ± 6.1 | 3.1 ± 3.3 | .16 | | |
| LOS indicates length of stay. Bold P values <.05 are statistically significant |

© 2020 Forum Multimedia Publishing, LLC
The veterans were receiving optimized medical treatment based on guidelines from the Cardiac Surgery Enhancement Program for VAMCs that started in 1991. Dual antiplatelet therapy with aspirin and Plavix was instituted in 2008. Additionally, our cardiothoracic surgery team has been experienced in OPCAB since 1998 due to the surgeon's preference, and the ancillary staff have been experienced in the perioperative process for patients. In addition, the Heart Center was established in 2015 to provide veterans comprehensive medical management, interventions, and follow-up care by coordinators, perfusionists, physician assistants, cardiologists, and cardiac surgeons. Therefore, the outcomes of the LMCAD patients did not differ significantly between the first and the second decades in this study (Table 4).

There are several limitations of this study. First, this study is a retrospective database study and therefore limited by the biases inherent to such a design. This study is also limited by the fact it reviews data from CABG surgeries performed at a single institution by a single surgeon experienced at OPCAB, and therefore it is unclear how generalizable these results are to the broader veteran population.

In conclusion, veterans with LMCAD who underwent CABG have similar postoperative complications compared to the non-LMCAD group except for increased length of hospital stay. The 30-day mortality is higher in the LMCAD group, as seen in the private sector. However, there is no difference in long-term survival between the two cohorts. Despite a higher comorbidity profile, veterans have similar outcomes when undergoing CABG for LMCAD when compared to the civilian population.

**REFERENCES**

Alexander JH, Smith PK. 2016. Coronary-artery bypass grafting. N Engl J Med 374:1954-64.

Authors/Task Force members, Windecker S, Kolh P, et al. 2014. ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Euro Heart J 35:2541-619.

Buszman PE, Buszman PP, Banasiewicz-Szkróbka I, et al. 2016. Left main stenting in comparison with surgical revascularization: 10-year outcomes of the (Left Main Coronary Artery Stenting) LE MANS trial. JACC: Cardiovasc Inter 9:318-27.

Cho SC, Park DW, Park SJ. 2019. Percutaneous coronary intervention and coronary artery bypass grafting for the treatment of left main coronary artery disease. Korean Circ J 49:69-83.

Deppe AC, Weber C, Liakopoulos OJ, et al. 2017. Preoperative intra aortic balloon pump use in high risk patients prior to coronary artery bypass graft surgery decreases the risk for morbidity and mortality—A meta-analysis of 9,212 patients. J Card Surg 32:177-85.

Fihn SD, Blankenship JC, Alexander KP, et al. 2014. ACC/AHA/ACCF/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 64:1929-49.

Harskamp RE, Vassiliades TA, Mehta RH, et al. 2015. Comparative effectiveness of hybrid coronary revascularization vs coronary artery bypass grafting. J Am Coll Surg 221:326-34.

Head SJ, Milojevic M, Daemen J, et al. 2018. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 391:939-48.

Lee PH, Ahn JM, Chang M, et al. 2016. Left main coronary artery disease: secular trends in patient characteristics, treatments, and outcomes. J Am Coll Surg 68:1233-46.

Modolo R, Chichareon P, Kogame N, et al. 2019. Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery for Left Main Disease. J Am Coll Surg 73:1877-86.

Morice MC, Serruys PW, Kappetein AP, et al. 2010. Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial. Circulation 121:2645-53.

Morice MC, Serruys PW, Kappetein AP, et al. 2014. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with TAXUS and cardiac surgery trial. Circulation 129:2388-94.

Nerlekar N, Ha FJ, Verma KP, et al. 2016. Percutaneous coronary intervention using drug-eluting stents versus coronary artery bypass grafting for unprotected left main coronary artery stenosis: a meta-analysis of randomized trials. Circ Cardiovasc Interv 9:e004729.

Ramadan R, Boden WE, Kinlay S. 2018. Management of left main coronary artery disease. J Am Heart Assoc 7:e008151.

Scherer LD, Fagerlin A. 2019. Shared Decision-Making in Revascularization Decisions: Complexities and Challenges. Circulation: Cardiovasc Qual Outcomes

Shroyer AL, Hartler B, Wagner TH, et al. 2017. Five-year outcomes after on-pump and off-pump coronary-artery bypass. N Engl J Med 377:623-32.

Stone GW, Sabik JF, Serruys PW, et al. 2016. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med 375:2223-2235.

Takaro T, Peduzzi P, Detre KM, et al. 1982. Survival in subgroups of patients with left main coronary artery disease. Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive Disease. Circulation 66:14-22.

Taggart DP, Kaul S, Boden WE, et al. 2008. Revascularization for unprotected left main stem coronary artery stenosis: stenting or surgery. J Am Coll Cardiol 51:885-92.

VA Coronary Artery Bypass Surgery Cooperative Study Group. 1992. Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. Circulation 86:121.

Vaughan-Sarrazin MS, Wakefield B, Rosenthal GE. 2007. Mortality of Department of Veterans Affairs patients undergoing coronary revascularization in private sector hospitals. Health Services Research 42:1802-21.